Neurocognitive Disorders

Latest News

Score Model Effectively Predicts Mortality Risk in Dementia

By

Abigail Nover

Eleven acute and chronic factors were identified for building a risk score model for predicting mortality in patients with dementia.

Dementia Tied to Anticholinergic Use

By

Natasha Persaud

In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.

Many Adults Worry About Developing Dementia

Many adults are worried about developing dementia and about half report taking steps to maintain or improve memory.

Positive Emotion Intervention Reduces Stress in Dementia Caregivers

The LEAF (Life Enhancing Activities for Family caregivers) intervention may help to reduce the stress of caregiving for a family member with dementia.

Cognitive Decline in Parkinson Disease Linked With Alzheimer Genetic Variants

By

Psychiatry Advisor Contributing Writer

Multiple genetic risk loci for Alzheimer disease predict longitudinal cognitive decline in patients with Parkinson disease without dementia.

Identifying Predictors of Suicidal Behavior in Huntington Disease

By

Psychiatry Advisor Contributing Writer

Researchers sought to identify variables that were associated with suicidal ideation or behavior in patients with Huntington disease.

FDA to Review Istradefylline NDA for Parkinson Disease Again

By

Da Hee Han, PharmD

Kyowa Hakko Kirin announced that the FDA has accepted the resubmitted NDA for istradefylline for use as adjunctive treatment to levodopa/carbidopa in adults with Parkinson disease experiencing OFF episodes.

CDC: 2000 to 2017 Saw Increase in Mortality Due to Dementia

Mortality attributed to dementia increased from 2000 to 2017, with variation by age, race, and sex.

Diet Quality in Midlife Not Linked to Later Risk for Dementia

Diet quality in midlife is not associated with subsequent dementia risk.

Efficacy of Cannabinoids for Agitation, Aggression in Alzheimer Disease Inconclusive

By

Laurel Ranger

The efficacy of cannabinoids on agitation and aggression in patients with Alzheimer disease remains inconclusive, but there might be a benefit with synthetic cannabinoids.